Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study

Phase 1
Completed
Conditions
Interventions
First Posted Date
2012-05-14
Last Posted Date
2014-11-25
Lead Sponsor
Knopp Biosciences
Target Recruit Count
15
Registration Number
NCT01597310
Locations
🇺🇸

Research Site, Overland Park, Kansas, United States

Warfarine in Unexplained Oligohydramnios

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2012-04-02
Last Posted Date
2021-01-07
Lead Sponsor
Woman's Health University Hospital, Egypt
Target Recruit Count
200
Registration Number
NCT01569035
Locations
🇪🇬

Women Health Hospital, Assiut, Egypt

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

First Posted Date
2012-03-23
Last Posted Date
2016-11-25
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
127
Registration Number
NCT01561937
Locations
🇺🇸

Novo Nordisk Investigational Site, Overland Park, Kansas, United States

Genetic Response to Warfarin in Healthy Subjects

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2012-01-30
Last Posted Date
2013-02-12
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
35
Registration Number
NCT01520402
Locations
🇺🇸

Mount Sinai School of Medicine, New York, New York, United States

Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke

First Posted Date
2012-01-25
Last Posted Date
2012-01-25
Lead Sponsor
Zhejiang Hospital
Target Recruit Count
40
Registration Number
NCT01518231
Locations
🇨🇳

Yaguo Li, Hangzhou, Zhejiang, China

Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients

First Posted Date
2012-01-25
Last Posted Date
2017-01-23
Lead Sponsor
Bayer
Target Recruit Count
40
Registration Number
NCT01516814

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

First Posted Date
2012-01-25
Last Posted Date
2017-01-18
Lead Sponsor
Bayer
Target Recruit Count
60
Registration Number
NCT01516840

A Drug-Drug Interaction Study of Warfarin and PA21

Phase 1
Completed
Conditions
Interventions
First Posted Date
2011-11-22
Last Posted Date
2012-02-16
Lead Sponsor
Vifor Pharma
Target Recruit Count
45
Registration Number
NCT01477424
Locations
🇺🇸

PRA International - Clinical Pharmacology Center, Lenexa, Kansas, United States

Anticoagulant After Implantation of Biological Aortic Valve Comparing With Aspirin

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-10-17
Last Posted Date
2014-08-05
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
370
Registration Number
NCT01452568

The Effect and Safety of Different Intensity Anticoagulation Therapy in Elderly Patients With Non-valvular Atrial Fibrillation

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-09-22
Last Posted Date
2012-05-21
Lead Sponsor
Nanjing Medical University
Target Recruit Count
260
Registration Number
NCT01438580
Locations
🇨🇳

First Affiliated Hospital of Nanjing Medical University, Division of Geriatrics, Nanjing, Jiangsu, China

© Copyright 2024. All Rights Reserved by MedPath